Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.

In the European Organization for Research and Treatment of Cancer (EORTC) classification 2 types of primary cutaneous large B-cell lymphoma (PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered important because of differences in prognosis (5-year survival > 95% and 52%, respectively) and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is not generally accepted. To establish a molecular basis for this subdivision in the EORTC classification, we investigated the gene expression profiles of 21 PCLBCLs by oligonucleotide microarray analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL into 2 distinct subgroups consisting of, respectively, 8 PCFCCLs and 13 PCLBCLsleg. PCLBCLs-leg showed increased expression of genes associated with cell proliferation; the proto-oncogenes Pim-1, Pim-2, and c-Myc; and the transcription factors Mum1/IRF4 and Oct-2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis suggested that PCFCCLs and PCLBCLs-leg have expression profiles similar to that of germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The results of this study suggest that different pathogenetic mechanisms are involved in the development of PCFCCLs and PCLBCLs-leg and provide molecular support for the subdivision used in the EORTC classification.

[1]  C. Meijer,et al.  Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[3]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Scarisbrick,et al.  Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. , 2002, The Journal of investigative dermatology.

[6]  H. Kerl,et al.  Primary cutaneous follicle center cell lymphoma with follicular growth pattern. , 2000, Blood.

[7]  B. Klein,et al.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.

[8]  C. Chang,et al.  Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. , 2002, Blood.

[9]  Sanjay Gupta,et al.  Stage-Specific Modulation of IFN-Regulatory Factor 4 Function by Krüppel-Type Zinc Finger Proteins1 , 2001, The Journal of Immunology.

[10]  J. Hanfelt,et al.  A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[12]  H Stein,et al.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.

[13]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[14]  R. Willemze,et al.  Primary Cutaneous Large B-Cell Lymphomas of the Legs: A Distinct Type of Cutaneous B-Cell Lymphoma With an Intermediate Prognosis , 1996 .

[15]  D. Rossi,et al.  Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. , 2002, Human pathology.

[16]  M. Seto,et al.  MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) , 2002, Japanese journal of cancer research : Gann.

[17]  M. Lohuizen,et al.  Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice , 1989, Nature.

[18]  T. Taniguchi,et al.  Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.

[19]  T. Hirano,et al.  Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.

[20]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Jaffe,et al.  Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Staudt,et al.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.

[23]  S. Whittaker,et al.  Comparative genomic hybridization analysis of primary cutaneous B‐cell lymphomas: Identification of common genomic alterations in disease pathogenesis , 2002, Genes, chromosomes & cancer.

[24]  R. Siebert,et al.  Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. , 2004, The Journal of investigative dermatology.

[25]  Katia Basso,et al.  Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.

[26]  J. Fanzo,et al.  Regulation of Lymphocyte Apoptosis by Interferon Regulatory Factor 4 (IRF-4) , 2003, The Journal of experimental medicine.

[27]  A. Sánchez-Aguilera,et al.  Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.

[28]  R. Warnke,et al.  Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. , 1993, Blood.

[29]  N. Pimpinelli,et al.  Primary cutaneous B‐cell lymphoma: A unique type of low‐grade lymphoma. Clinicopathologic and immunologic study of 83 cases , 1991, Cancer.

[30]  A. Zeiher,et al.  Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway , 2000, Molecular and Cellular Biology.

[31]  C. Meijer,et al.  Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. , 1987, Journal of the American Academy of Dermatology.

[32]  A. Berns,et al.  Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc , 1997, Oncogene.

[33]  G. Fleuren,et al.  Bcl‐2, Bcl‐6 and CD10 expression in cutaneous B‐cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance , 2003, The British journal of dermatology.

[34]  R. Willemze,et al.  Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. , 1996, Archives of dermatology.

[35]  H. Prince,et al.  Clinical study of primary cutaneous B‐cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications , 2003, The Australasian journal of dermatology.

[36]  T. Jacks,et al.  Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. , 1993, Genes & development.

[37]  C. Meijer,et al.  bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Grzeschik,et al.  Organization and sequence of the gene encoding the human acrosin-trypsin inhibitor (HUSI-II). , 1993, Gene.

[39]  S. Whittaker,et al.  Absence of the t(14; 18) chromosomal translocation in primary cutaneous B‐cell lymphoma: reply from authors , 2002, The British journal of dermatology.

[40]  R. Warnke,et al.  Cutaneous Follicular Lymphoma , 1986, The American journal of surgical pathology.

[41]  H. Ohno,et al.  Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Mak,et al.  Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.

[43]  T. Yoshino,et al.  Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. , 1992, Blood.

[44]  R. Siebert,et al.  Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. , 2004, The Journal of investigative dermatology.

[45]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[46]  P. McKay,et al.  Primary Cutaneous Diffuse Large B-cell Lymphoma: Prognostic Significance of Clinicopathological Subtypes , 2003, The American journal of surgical pathology.

[47]  K. Becker,et al.  Analysis of microarray data using Z score transformation. , 2003, The Journal of molecular diagnostics : JMD.

[48]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[49]  D. Delia,et al.  Reticulohistiocytoma of the dorsum. , 1988, Journal of the American Academy of Dermatology.

[50]  A. Calastretti,et al.  Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. , 2001, European journal of cancer.

[51]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.